inhibition at higher concentrations (site NS2). In the current study, compound 3α5β-18-norACN (3α,5β,17β)-3-hydroxy-18-norandrostane-17-carbonitrile), an 18-norsteroid, is shown to be a full agonist at site NS1 and a weak partial agonist at site NS2 in both rat brain membranes and heterologously expressed GABA A receptors. 3α5β-18-norACN also inhibits the action of a full neurosteroid agonist, (3α,5α,17β)-3-hydroxy-17-carbonitrile (3α5αACN) at site NS2. Structure-activity studies demonstrate that absence of the C18 methyl group and the 5β-reduced configuration both contribute to the weak agonist effect at the NS2 site. Electrophysiological studies using heterologously expressed GABA A receptors show that 3α5β-18-norACN potently and efficaciously potentiates the GABA currents elicited by low concentrations of GABA, but has low efficacy as a direct activator of GABA A receptors. 3α5β-18-norACN also inhibits direct activation of GABA A receptors by 3α5αACN. 3α5β-18-norACN also produces loss of righting reflex in tadpoles and mice, indicating that action at NS1 is sufficient to mediate the sedative effects of neurosteroids. These data provide insight into the pharmacophore required for neurosteroid efficacy at the NS2 site and may prove useful in the development of selective agonists and antagonists for neurosteroid sites on the GABA A receptor.
JPET # 164079

INTRODUCTION
Certain endogenous pregnane steroids and their synthetic analogues modulate the function of GABA A receptors (Lambert et al., 2003) . These neuroactive steroids potentiate the actions of GABA at low concentrations and directly open GABA A receptor channels at higher concentrations (Barker et al., 1987; Cottrell et al., 1987) . Several lines of evidence suggest that multiple neuroactive steroid recognition sites contribute to GABA A receptor modulation. Radioligand binding studies have shown that pregnanolone (3α,5β)-3-hydroxypregnan-20-one) modulation of [
35 S]t-butylbicyclophosphorothionate (TBPS), JPET # 164079 examined the anesthetic efficacy of compound 3α5β-18-norACN to determine if the anesthetic actions of neurosteroids require agonism at both neurosteroid sites.
METHODS Prepared materials:
The synthesis, spectroscopic and physical properties of 3α5αACN, 3α5βACN, were reported by us previously (Han et al., 1996; Hu et al., 1993) . The 18-nor and 18,19-dinorsteroids were prepared by similar multistep synthetic procedures. Briefly, the 18-methyl group was removed from either a 17-ketosteroid or 19-nor-17-ketosteroid precursor to give the corresponding 18-nor or 18,19-dinorsteroids. The seven-step procedure required for removal of the 18-methyl group has been described by us for the preparation of other 18,19-dinor-17-ketosteroids (Han and Covey, 1996) . The 17-keto group of the 18-nor or 18,19-dinorsteroids was then converted in two steps into the 17-carbonitrile group using a procedure we described previously (Han et al., 1996) . Conversion of the 17-carbonitrile group into the acetyl group of 20-ketopreganes was also described by us previously (Han et al., 1996) . The spectroscopic and physical properties of the previously unknown 18-nor and 18, 19-dinorsteroids used in this study are given below.
3α5α-18-norACN: colorless crystals (from ethyl acetate/hexanes), mp 157-159 ˚C; IR 3413, 2238 cm -1 ;
JPET # 164079
Vector construction: cDNA constructs for GABA A receptor subunits were provided by A. Tobin, University of California Los Angeles (rat α 1 ) and D. Weiss, University of Texas, San Antonio, TX (rat β 2 ). The expression construct for the rat α 1F pcDNA3, rat β 2 pcDNA3 and rat α 1myc were previously described (Darbandi-Tonkabon et al., 2003; Ueno et al., 1996) . The rat β 2F construct was made by PCR mutagenesis inserting the FLAG between amino acids 4 and 5 using the oligonucleotides: rat β 2F forward: 5' gattacaaggacgatgacgacaaggaccctagtaatatgtcgctgg 3'; and rat β 2F reverse: 5' cttgacgacatcgtccttgtaatcattgacactctgagcacagacagc 3'. All inserts were sequenced through the entire coding region.
Tissue culture: Quail fibroblast (QT-6) cells were maintained in culture using standard methods and passaged at subconfluent densities. A stably transfected cell line with rat α 1myc rat β 2Flag was produced in QT-6 cells by standard methods. In brief, QT-6 cells were transfected with the cDNA using the calcium phosphate precipitation method or using Effectene (Qiagen, Valencia, CA). Cells resistant to G418 were selected. A population of cells expressing high levels of surface FLAG was selected by immunoselection using the anti-FLAG antibody (M2; Sigma) (Chen et al., 1995) .
Membrane preparation: Rat brains were purchased from Pel-Freez (Rogers, AK) and stored until use at -80°C. Cerebella and brain stem were trimmed from the frozen brains and the cerebral hemispheres were used. Membranes for structure-activity relationship experiments (Tables 1 and 2) were prepared using minor modifications of the method of Hawkinson (Hawkinson et al., 1994a) , as previously described JPET # 164079 resuspended in distilled water (12 ml/brain) and stirred for 30 minutes at 4˚ C. Membranes were then collected by centrifugation for 45 min at 100,000g at 4˚ C. The pellet was washed twice with buffer (20 mM K-Phosphate, 50 mM KCl, pH 7.5). The membranes were pelleted after each wash by centrifugation for 45 min at 100,000g at 4˚C. After the final centrifugation, membranes were resuspended in assay buffer (10 mM K-Phosphate, 100 mM KCl, pH 7.5) at approximately 5 mg membrane protein /ml and stored at -80˚C.
QT-6 cell membranes were prepared as follows: Cells were grown in monolayer culture to 70-80% confluency on 150 cm plates. The plates were washed twice with 5 ml ice-cold phosphate-buffered saline containing 0.1% protease inhibitor cocktail (Sigma Chemical, St. Louis, MO). 5 ml of TEN (10 mM TrisHCl, 1 mM EDTA, 100 mM NaCl, pH 7.5, 0.1% protease inhibitor cocktail) was added to each plate, and cells were scraped from the plate with a rubber cell scraper. The plates were washed with 5 ml of TEN and the harvested cells were collected by centrifugation for 10 min at 5000g at 4°C. Cells were resuspended in TEN and homogenized using a Tekmar Ultra-Turrax (ten 5-sec bursts at 4°C). Membranes were then collected by centrifugation for 30 min at 30,000g at 4°C, resuspended in TEN (2-3 mg protein/ml) and stored in aliquots at -80°C. (final steroid concentrations ranged from 1 nM to 10 μ M), in a total volume of 1 ml of assay buffer. For rat brain membranes the assay buffer was 100 mM KCl, 10 mM K-Phosphate buffer, pH 7.5; for QT-6 cell membranes assay buffer was 20 mM Tris-HCl, 1 M NaCl, pH 7.5; for the structure-activity screens shown in tables, the assay buffer was 50 mM K-phosphate buffer, pH7.4, 200 mM NaCl. GABA (5 μ
M)
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where B is steroid bound, Z is the starting maximum binding in the absence of steroids; A is the amplitude of the enhancement, K 1 is the half-maximal enhancement concentration, K 2 is the half-maximal inhibition concentration, and [C] is steroid concentration.
All fits were performed using Sigma Plot version 8 (SPSS; Chicago IL) and Prism GraphPad (San Diego, CA).
Xenopus Oocyte electrophysiological methods. Stage V-VI oocytes were harvested from sexually mature female X. laevis (Xenopus One, Northland, MI) under 0.1% tricaine (3-aminobenzoic acid ethyl ester) anesthesia. Oocytes were defolliculated by shaking for 20 min at 37°C in collagenase (2 mg/ml) dissolved in calcium-free solution containing (in mM): 96 NaCl, 2 KCl, 1 MgCl 2 , and 5 HEPES at pH 7.4. Capped mRNA encoding rat GABA A receptor α 1 , β a resistance of ~ 1 MΩ when filled with 3 M KCl. Compounds were simultaneously co-applied with GABA using a gravity-flow perfusion system. Holding potential was -70 mV, and peak current during 20 s drug applications was used for quantification. Data were acquired and analyzed with pCLAMP software (Molecular Devices, Sunnyvale, CA). Statistical differences were determined using a two-tailed Student's
t-test.
Tadpole and mouse anesthetic assay: Assays for neuroactive steroid-induced loss-of-righting reflex (LRR) in Xenopus laevis tadpoles and in BALB/c mice were performed as previously described (Covey et al., 2000) . Briefly, groups of 10 early prelim-bud stage Xenopus laevis tadpoles (Nasco. Fort Atkinison, WI) were placed in 100 ml of oxygenated Ringer's buffer containing varying concentrations of 3α5β-18-norACN. After 3 h of equilibration the tadpoles were assessed for the loss-of-righting reflex (LRR) and loss-of-swimming (LSR) reflex behavioral endpoints. LRR was defined as failure of the tadpole to right itself within 5 s after being flipped by a smooth glass rod. LSR was defined as failure to initiate swimming after being flipped by a smooth glass rod. Concentration-response curves were fit to the Hill equation using Sigma Plot version 8.0. For the mouse assay, BALB/C mice were injected i.v. through a tail vein with various doses of 3α5β-18-norACN in an 8% ethanol, 16% cremophor EL (Sigma Chemical Co.) solution. LRR was defined as inability of mice to right themselves within 5 s after being placed in a prone position. LRR time was measured from the moment mice displayed LRR until they were able to right themselves.
RESULTS
Structures:
The structures of the neuroactive steroid analogues used in this study are shown in Figure 1 .
The structural variables were the 5α-vs. 5β-configuration, and the presence or absence of the C18 and/or C19 methyl groups. Structural variables were examined both in steroids with an acetyl group at carbon 17 (naturally occurring neurosteroids) and with a carbonitrile substitution at carbon 17.
This article has not been copyedited and formatted. The final version may differ from this version. Membranes from QT-6 cells expressing α 1 β 2 GABA A receptor subunits were modulated by 3α5αACN in a manner very similar to that observed in rat brain membranes. In the absence of GABA, 3α5αACN stimulated TBPS binding at low concentrations (EC 50 =28 ± 14 nM) and inhibited at higher concentrations (IC 50 =537 ± 115 nM). In the presence of GABA (1 μM), 3α5αACN inhibited TBPS binding with an IC 50 of 20 ± 9 nM and a Hill slope =1 ( Figure 4A ). 3α5β-18-norACN appeared to be a selective NS1 agonist in α 1 β 2 receptors ( Figure   4B Figure 5A shows superimposed traces of representative currents elicited by 2 μM GABA alone (the lowest amplitude trace) and 2 μM GABA plus 0.1, 1 or 10 μM 3α5β-18-norACN, 3α5βACN, or 3α5αACN. The concentrationresponse curves ( Figure 5B ) demonstrate that 3α5αACN (Emax= 14± 21) has modestly higher efficacy than 3α5β-18-norACN (Emax= 10 ± 0.3) or 3α5βACN (Emax= 7.8 ± 1.6) in potentiating GABA-elicited currents. However, there is no statistical difference among them.
Two-way ANOVA indicated that 0.3, 1, and 3 μM 3α5αACN had higher potentiation than 3α5β-18-norACN and 3α5βACN. However, there was no difference among these three neurosteroids at 10 μM. with EC 50 values of 0.6 ± 0.1, 1 ± 0.4, and 0.2 ± 0.4 μM, respectively. These results indicate that there is not a major difference in potency or efficacy among 3α5αACN, 3α5β-18-norACN, and 3α5βACN in potentiating GABA-elicited currents.
The ability of 3α5β-18-norACN, 3α5αACN and 3α5βACN to directly activate GABA A receptors in the absence of GABA was also examined. In order to decrease differences among oocytes, the direct gating currents were normalized to currents elicited by 2 μM GABA in the same cell. Figure 6A shows representative traces of steroid-elicited currents in comparison with 2 μM GABA. As shown in Figure 6B , 3α5β-18-norACN elicited very small GABA currents compared to 3α5αACN; 30 μM 3α5β-18-norACN gated a current 1.7 ± 0.2 % as large as that elicited by 2 μM GABA. Based on this low efficacy concentration-response curve ( Figure 6B , lower panel), the observed EC 50 of 3α5β-18-norACN for direct gating was 1.6 ± 0.4 μM. 30 μM 3α5βACN elicited currents equal to 5.0 ± 0.2 % of the 2 μM GABA currents, with an EC 50 of 3.3 ± 0.2 μM. 3α5αACN showed much higher gating efficacy; 30 μM 3α5αACN elicited currents were as large as 34 ± 2.4 % of 2 μM GABA. The EC 50 of 3α5αACN could not be accurately determined since maximum effect was not achieved at concentrations that maintained solubility.
The low efficacy of 3α5β-18-norACN, coupled with its relatively high apparent potency as a direct activator of GABA A currents suggested that it might antagonize the actions of more efficacious neurosteroids at the site mediating direct activation. To test this idea, we examined the ability of 10 μM 3α5αACN to directly activate currents in the presence and absence of 30 µM 3α5β-18-norACN. The currents elicited by 10 μM 3α5αACN and 30 µM 3α5β-18-norACN were 0.40 ± 0.05 µA and 0.03 ± 0.01 µA, respectively ( Figure 6C ). 30 µM 3α5β-18-norACN dramatically decreased the current elicited by 10 μM 3α5αACN. In the presence of 3α5β-18-norACN, the current elicited by 10 μM 3α5αACN was 0.10 This article has not been copyedited and formatted. The final version may differ from this version. Figure 7A ). Our previous work showed that the EC 50 values for LRR by 3α5αACN, 3α5αP, 3α5βACN, and 3α5βP in tadpoles were 70 ± 10 nM, 390 ± 40 nM, 80 ± 13nM, and 61± 4 nM, respectively (Covey et al., 2000; Wittmer et al., 1996) . They are not statistically significantly different compared to 3α5β-18-norACN. 1.0 μM 3α5β-18-norACN caused no LSR. However, 3 and 10 μM μM 3α5β-18-norACN caused LSR in all tadpoles. The ability of 3α5β-18-norACN to anesthetize mice was also examined. 3α5β-18-norACN produced loss of righting reflex at a threshold dose of ≈9 mg/kg i.v. This is similar to the threshold dose of 4 mg/kg for 3α5αACN to produce loss of righting reflex (Wittmer et al., 1996) . The duration of loss of righting reflex was dose-dependent ( Figure 7B ).
DISCUSSION
This paper demonstrates that compound 3α5β-18-norACN (previously named B285 (Akk et al., 2004) ), a 5β-reduced steroid lacking the 18-methyl group, binds to steroid sites NS1 and NS2 on GABA A receptors, acting as an agonist at the NS1 site and as a weak partial agonist at the NS2 site. Both the 5β-reduced configuration and the absence of the 18-methyl group contribute to the low efficacy of 3α5β-18-norACN at the NS2 site. 3α5β-18-norACN also selectively potentiates GABA-elicited currents but produces minimal direct activation of GABA A receptor currents; it appears to be a weak partial agonist at the site mediating direct activation of GABA A receptors, as it reduces the direct activation of GABA A currents elicited by 3α5αACN. Finally, our model assumes that as GABA concentration is increased, GABA sequentially occupies its two binding sites. This implies that at low GABA concentration mono-liganded receptors will predominate, whereas di-liganded receptors will be the principal species at high GABA concentrations.
The above assumptions about TBPS and neurosteroid (NS1 and NS2) stoichiometry and GABA site Action of 3α5β-18-norACN on TBPS binding. 3α5β-18-norACN behaves as a selective NS1 site agonist. In the absence of GABA (RS1 in Figure 8 ), it enhances TBPS binding at low concentrations and minimally inhibits TBPS binding at higher concentrations ( Figure 2D ). 3α5β-18-norACN also occludes the NS1 actions of 3α5αACN, indicating that these two ligands compete for binding at site NS1 and have similar efficacy ( Figure 3A) . In contrast, while 3α5β-18-norACN alone produces no NS2 site effect, increasing concentrations of 3α5β-18-norACN antagonize the actions of 3α5αACN as an NS2 site agonist ( Figure 3B ); this suggests that 3α5β-18-norACN occupies the NS2 site but has minimal efficacy.
In the presence of 5 μM GABA (Figure 2 , 1996; Morrow et al., 1990; Xue et al., 1997) . These compounds may also be selective ligands for either the NS1 or NS2 sites. The EC 50 for LRR was 164 ± 40 nM (S.E.). 0.3 μM 3α5β-18-norACN has no effect on LSR, whereas 1 and 3 μM 3α5β-18-norACN produce LSR in all the tadpoles. B. Intravenous injection of 3α5β-18-norACN produced dose-dependent LRR (sleep times) in mice. Points ± S.E. on the mouse dose-response curve represent the average sleep time for three or four animals and were fit to a straight line. 
